Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Medicus Pharma Ltd. (MDCX)

1.8850 +0.0150 (+0.80%)
At close: November 9 at 4:00:00 PM EST
1.8880 +0.0030 (+0.16%)
After hours: November 9 at 5:39:26 PM EST
MDCX Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for MDCX
Chart does not reflect overnight price.
  • Previous Close 1.8700
  • Open 1.8700
  • Bid 0.1600 x 100
  • Ask 1.9900 x 1200
  • Day's Range 1.7891 - 2.1648
  • 52 Week Range 1.7000 - 127.5000
  • Volume 61,443
  • Avg. Volume 110,562
  • Market Cap (intraday) 3.58M
  • Beta (5Y Monthly) 0.15
  • PE Ratio (TTM) --
  • EPS (TTM) -119.0000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 203.75
  • Moby Rating Neutral

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.

medicuspharma.com

16

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDCX
97.54%
S&P 500 (^GSPC)
10.29%

1-Year Return

MDCX
98.42%
S&P 500 (^GSPC)
12.20%

3-Year Return

MDCX
98.78%
S&P 500 (^GSPC)
73.67%

5-Year Return

MDCX
98.78%
S&P 500 (^GSPC)
61.14%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -15.18M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

15.00
203.75 Average
1.8850 Current
450.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/20/2026
Analyst D. Boral Capital
Rating Action Maintains
Rating Buy
Price Action Maintains
Price Target 9 -> 9

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -110.67%

  • Return on Equity (ttm)

    -7,446.11%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -56.66M

  • Diluted EPS (ttm)

    -119.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.17M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -16.16M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: